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Abstract. Hepatocellular carcinoma (HCC) is the most 
common type of liver cancer, and the fourth leading cause 
of cancer mortality worldwide. It is often diagnosed at an 
advanced stage, and hence typically has a poor prognosis. A 
number of distinct molecules have been recently identified as 
playing a role in the control of cancer progression. However, 
patients with HCC have a highly variable clinical course, 
indicating that HCC comprises several biologically distinctive 
subgroups reflecting a molecular heterogeneity of the tumors. 
To evaluate potential biomarkers in HCC, we employed 
multiple methods in this study, including qPCR, immunos-
taining methods and tissue microarrays (TMAs), as well as 
histological and pathological analysis, to assess TGFβ, XPO4, 
elF5A2 and ANGPTL4 in cancerous and paracancerous liver 
tissues from 280 patients suffering from liver cancer. Our 
results found that all four indicators were located in the cyto-
plasm and distributed in cancerous and paracancerous liver 
tissues. Generally, there were higher levels of these indicators 
in paracancerous, compared with cancerous, liver tissues. 
These four indicators were correlated and modulated among 
each other. In connection with patient clinical and revisit 
information, statistical analysis determined that TGFβ1 in 
paracancerous liver tissue was positively correlated with 
tumor size. Higher production of TGFβ1 in paracancerous 
liver tissue was always associated with bigger liver tumors. 
XPO4 in cancerous liver tissue and TGFβ1 in paracancerous 
liver tissue were positively correlated with tumor differen-
tiation. TGFβ1, ANGPTL4 and elF5A2 were also positively 
correlated with the T classification of tumors. Additionally, 
higher levels of XPO4 in cancerous liver tissue suggested 
that the patient would have a better prognosis and survival 
rate. However, higher production of XPO4 in paracancerous 
liver tissue suggested a worse prognosis. All the results above 
provide new insights into better understanding biological 
indicators, such as XPO4, TGFβ1, ANGPTL4 and elF5A2, 
in the prediction and evaluation of liver cancer, as well as 
signaling pathways in the control of liver cancer. XPO4 and 
TGFβ1 may serve as useful markers to evaluate the size and 
prognosis of liver cancer.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common 
malignant tumors worldwide with an extremely high incidence 
and poor survival rate (1,2). The management of patients at 
risk for developing HCC remains an intricate process. Despite 
the large number of studies devoted to the immunohistochem-
istry of HCC, at the present time, the definitive positive and 
negative markers for HCC are lacking. 
Several key molecules in signaling pathways involved in 
cancer development have emerged. TGFβ plays an important 
role in the regulation of cell growth and differentiation, angio-
genesis, extracellular matrix formation, immunosuppression 
and cancer development (3). It is well known that signaling by 
the TGFβ family is most prominent at the interface between 
normal tissue development and cancer. The TGFβ signaling 
pathway is activated upon ligands binding to type I and II trans-
membrane receptors. The Smad4 protein is the downstream 
mediator of TGFβ. Phosphorylation of Smad, by activation of 
TGFβ receptors, results in activation of a TGFβ‑targeted gene. 
ELF associates with SMAD3, presenting it to the cytoplasmic 
domain of the TGFβ receptor complex; this has been found to 
play a pivotal role in TGFβ signaling (4). Dysfunction of TGFβ 
pathway members, including TGFβR2, SMAD3, SMAD4 
and ELF, may lead to progenitor/stem cell deregulation and 
possibly cancer formation. Previous studies have suggested 
that Smad3 and its phosphorylation relatives may be used 
as biomarkers to identify patients with a high risk of recur-
rence (5,6). Smad3 is exported via XPO4. XPO4 is therefore in 
control of Smad3 signaling as well as protein synthesis (7,8). 
A recent study indicated that XPO4 may be involved in the 
progression of human HCC and may serve as a potential target 
for gene therapy in its treatment  (9). We consequently selected 
XPO4 as an indicator in the current study.
HCC recurrence commonly occurs with an extremely poor 
prognosis. Vascular invasion in HCC is one of the key factors 
that results in cancer recurrence. To invade, HCC cells must 
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penetrate the vessel wall, which consists of endothelial cells 
and extracellular matrix components, including fibronectin and 
fibrinogen. TGFβ specifically phosphorylates integrinβ1 via 
Smad-2 and Smad-3, causing a conformational change of the 
extracellular component with an inside-out mechanism (10). 
Additionally, a previous study in breast cancer revealed that the 
induction of ANGPTL4 by TGFβ via Smad disrupts vascular 
endothelial cell-cell junctions, increases the permeability of 
lung capillaries and facilitates the trans-endothelial passage of 
tumor cells (7,11-14). 
Therefore, we employed multiple methods to assess 
TGFβ, XPO4, elF5A2 and ANGPTL4 in cancerous and 
paracancerous liver tissue samples obtained from 280 patients 
suffering from liver cancer. We aimed to determine whether 
these four indicators may become biomarkers to evaluate HCC 
and provide an improved prognosis. 
Patients and methods
Patients and samples. Samples were obtained under informed 
consent from 280 patients with HCC who underwent surgery 
to remove liver cancer between 2005 and 2011 in our hospital 
(Fudan University, Shanghai, China). All cases met the criteria 
set by the University of California, San Francisco (UCSF) (15). 
The follow-up of cases was at a mean of 42 months (range, 
3-84 months). In patients with multi-nodular tumors, tumor 
samples were obtained from the largest tumor. Ethical 
approval was obtained from the Hua Shan Hospital Research 
Ethics Committee.
Tissue microarray (TMA) arrangement. TMA blocks were 
constructed as described previously (16). Briefly, all HCC 
tissues were reviewed by two histopathologists. Representative 
tumor areas free from necrotic and hemorrhagic materials were 
premarked in the paraffin blocks. Two cores, 1.5 or 2.0 mm in 
diameter, were taken from each representative tumor tissue, 
and from liver tissue adjacent to the tumor, and transferred 
from the recipient paraffin block at defined array positions. Six 
TMA blocks were constructed. Consecutive sections of 4-µm 
thickness were taken on 3-aminopropyltriethoxysilane-coated 
slides (Shanghai Outdo Biotech Co., Ltd., Shanghai, China).
qPCR. RNA isolation and qRT-PCR was used. Total RNA was 
extracted from frozen tumor specimens and matched liver 
tissue adjacent to the tumor from 16 HCC patients using 
TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, 
USA) according to the manufacturer's instructions. XPO4, 
TGFβ1, ANGPTL4 and elF5A2 mRNA expression in tissues 
from these patients was measured by qRT-PCR using an IQ5 
instrument (Bio-Rad, Hercules, CA, USA). qRT-PCR was 
performed using a SYBR PrimeScript RT-PCR kit (Takara 
Bio, Inc., Shiga, Japan) according to the manufacturer's 
instructions. GAPDH was used as an internal control. The 
primers were as follows: XPO4 (Genbank NM_022459.4) 
forward primer 5'-TTGTTCTTGGTGTTTTGTGTTTCC-3' 
and reverse primer 5'-CATTCCTTTCCCACTCCTCTT 
TAG-3'; TGFβ1 (Genbank NM_000660.3) forward primer 
5'-GCAACAATTCCTGGCGATACCT-3' and reverse primer 
5'-CAGTGTGTTATCCCTGCTGTCACA-3'; ANGPTL4 
(Genbank NM_001039667.1) forward primer 5'-GACCAA 
GGGGCATGGAGCTT-3' and reverse primer 5'-CAGGGG 
ACCTACACACA ACAG CA-3';  el F5A 2 (Genba n k 
NM_020390.5) forward primer 5'-TTGTTCTCAGGG 
CTATTTGTGCTAA-3' and reverse primer 5'-GGATGCTAC 
TGTTTCCATTTTTTTC-3'; and GAPDH (Genbank 
NM_002046.3) forward primer 5'-TCCCTCAACATTGTC 
AGCAA-3' and reverse primer 5'-AGCTCCACAACGGAT 
ACATT-3'. Relative mRNA levels were calculated based on 
the Ct values and corrected for GAPDH expression, according 
to the equation: 2-ΔCt [ΔCt = Ct (target gene) - Ct (GAPDH)]. 
All experiments were performed in triplicate.
Immunostaining. The primary antibodies used for immuno-
histochemistry were XPO4 (polyclonal rabbit, diluted 1:100; 
PAB0297, Abnova, Taipei, Taiwan), TGFβ1 (monoclonal 
mouse, diluted 1:3,000; MAB2505, Abnova), ANGPTL4 
(monoclonal mouse, diluted 1:200; L191591e, Enzo, NY, 
USA) and elF5A2 (polyclonal rabbit, diluted 1:30; E9781, 
Sigma, St. Louis, MO, USA). Immunohistochemistry was 
carried out using a two-step method as described previ-
ously (16). Following heat-induced antigen retrieval, tissues 
were incubated with primary antibodies for 30 min at room 
temperature. Following a 30-min incubation with a matched 
secondary antibody, sections were developed in 3,3'-diamino-
benzidine solution (Sigma) under microscopic observation and 
counterstained with hematoxylin (Sigma). Negative control 
slides in which the primary antibodies had been omitted were 
included in all assays.
Statistical analysis. Analysis was performed with SPSS 17.0 
for Windows (SPSS Inc., Chicago, IL, USA); the values are 
expressed as the mean ± standard error. A two-tailed P-value 
of <0.05 was considered to indicate a statistically significant 
difference. The differential expression of proteins between 
carcinoma tissue and adjacent tissue was determined by a 
t-test. In statistics, correlation refers to any of a broad class 
of statistical relationships involving dependence. The most 
common method is the Pearson correlation coefficient (CC), 
which is sensitive only to a linear relationship between two 
variables. Two variables are more correlative if the CC value 
is closer to 1. Relationships between clinicopathological 
and molecular parameters were statistically analyzed using 
Pearson or Spearman's rank correlation coefficients. P<0.05 
indicates that the two groups are correlative. Kaplan-Meier 
analysis was used to determine survival. The log-rank test was 
then used to compare patient survival between subgroups.
Results
Distribution of indicators in liver tissues. The four indicators, 
XPO4, TGFβ1, ANGPTL4 and elF5A2, were found to be 
located within the cellular cytoplasm by the immunostaining 
method (Fig. 1). The data shown in Table I are based on the 
immunohistochemical staining levels. The values in the table 
were obtained from the percentage of positive staining in the 
same samples among TMAs. With regard to tissue distribution 
of the 4 indicators, they were all expressed in cancerous and 
paracancerous liver tissues. They were all found at a signifi-
cantly higher density in the paracancerous tissues than in the 
cancerous liver tissues (Table I).
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Correlation in expression among these indicators. The 
correlation in expression of XPO4 between the cancerous 
and paracancerous liver tissue was positive (CC=0.304, 
P<0.001). Expression of XPO4 in the cancerous liver 
tissue was positively correlated with expression of TGFβ1 
(CC=0.126, P=0.047) in paracancerous liver tissue, expres-
sion of ANGPTL4 (CC=0.506, P=0.000) in cancerous liver 
tissue, expression of ANGPTL4 (CC=0.199, P=0.002) in para-
cancerous liver tissue and expression of elF5A2 (CC=0.194, 
P=0.002) in paracancerous liver tissue (Table II). The correla-
tion in expression of ANGPTL4 between the cancerous and 
paracancerous liver tissue was positive (CC=0.282, P<0.001). 
Expression of ANGPTL4 in the cancerous liver tissue was 
positively correlated with expression of XPO4 (CC=0.506, 
P<0.001) in carcinoma liver tissue, expression of elF5A2 
(CC=0.469, P<0.001) in carcinoma liver tissue and expression 
of elF5A2 (CC=0.245, P<0.001) in paracancerous liver tissue. 
The correlation in expression of elF5A2 between cancerous 
and paracancerous liver tissues was positive (CC=0.371, 
P<0.001). Expression of elF5A2 in the cancerous liver tissue 
was positively correlated with expression of XPO4 (CC=0.478, 
P<0.001) in carcinoma liver tissue. These results suggest that 
the expression of these four indicators is internally connected 
and there is modulation between each of them. 
Correlation between expression of indicators and patho-
logical information
Indicators and tumor size. In patients with multi-nodular 
tumors, the tumor samples were obtained from the largest 
tumor. The statistical results revealed that the expression of 
TGFβ1 in paracancerous liver tissue was significantly posi-
tively correlated with tumor size (CC=0.147, P=0.021, n=248; 
Table III). The other 7 parameters, e.g., TGFβ1 in cancerous 
liver tissue, and XPO4 in cancerous liver tissue, had no signifi-
cant correlation with tumor size. 
Indicators and blood vessel invasion The statistical results 
revealed that all indicators in cancerous and paracancerous 
liver tissues had no significant correlation with blood vessel 
invasion (Table IV).
Indicators and pathological classification (differentia-
tion). The patients were divided into two categories according 
to the Edmondson classification; high differentiation (I, II, 
I-II) and low differentiation (II-III, III, IV). The statistical 
results revealed that all indicators exhibited higher expres-
sion levels in the low differentiation group than in the high 
differentiation group (Table V). XPO4 in cancerous liver 
tissue (CC=0.143, P=0.035) and TGFβ1 (CC=0.195, P=0.004) 
in paracancerous liver tissue were significantly correlated 
with tumor differentiation. 
Indicators and tumor T classification The statistical 
results revealed that expression of TGFβ1 in both cancerous 
and paracancerous tissues (CC=0.402, P=0.000; CC=0.299, 
P=0.000, respectively) was positively correlated with T 
classification; expression of ANGPTL4 in cancerous and 
paracancerous liver tissues (CC=0.125, P=0.049; CC=0.142, 
P=0.025, respectively) was positively correlated with T clas-
sification and that the expression of elF5A2 in paracancerous 
liver tissues (CC=0.127, P=0.047) was positively correlated 
with T classification.
Indicators and survival function. Kaplan-Meier analysis 
indicated that the expression of XPO4 in carcinoma tissue 
did not correlate with survival function in overexpression 
and underexpression (P=0.202). The survival plot indicated 
that survival rates in patients with XPO4 overexpression 
were higher than those in patients with XPO4 underex-
pression (Fig. 2A). Expression of XPO4 in adjacent tissue 
did not correlate with overexpression or underexpression 
(P=0.139). The survival plot indicated that survival rates in 
patients with XPO4 overexpression in adjacent tissues were 
lower than those in patients with XPO4 underexpression. 
These results suggested that higher expression of XPO4 in 
cancerous liver tissue was indicative that the patient would 
have a better prognosis and increased survival rate. However, 
higher concentrations of XPO4 in paracancerous liver tissue 
suggested a worse prognosis (Fig. 2B). Furthermore, expres-
sion of TGFβ1 in carcinoma tissue did not correlate with 
overexpression or underexpression (P=0.954). The survival 
figure indicated that patients who were positive for TGFβ1 in 
cancerous liver tissue had a better prognosis than those who 
were negative for TGFβ1 in cancerous liver tissue (Fig. 3). 
Other factors, e.g., ANGPTL4 and ELF, were not correlated 
with overexpression or underexpression in either of the 
cancerous and adjacent tissues.
Discussion 
In the present study, we employed multiple techniques, 
including the use of qPCR, immunostaining and TMAs, 
as well as histology and pathology analysis, to undertake a 
study to evaluate XPO4, TGFβ1, ANGPTL4 and elF5A2 in 
carcinoma and paracarcinoma tissues from 280 liver cancer 
patients. Our results revealed that all four indicators were 
Table I. Expression of XPO4, TGFβ1, ANGPTL4 and elF5A2.
Indicator Carcinoma tissue Adjacent tissue P-valuea
XPO4 0.800±0.194 0.855±0.113 0.000
TGFβ1 0.256±0.284 0.502±0.312 0.000
ANGPTL4 0.723±0.247 0.817±0.173 0.000
elF5A2 0.770±0.176 0.814±0.141 0.000
aPaired‑sample t‑test. P<0.05 was considered to indicate a statistically significant difference. XPO4, TGFβ1, ANGPTL4 and elF5A2 expression 
in carcinoma tissues was significantly lower than that in adjacent tissues.
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located in the cytoplasm and distributed in both cancerous and 
paracancerous liver tissues. Generally, there were higher levels 
of these indicators in paracancerous than in cancerous liver 
tissue. The correlation analysis results further revealed that 
expression levels of these four indicators were correlated and 
modulated amongst each other. In connection with patients' 
clinical and revisit information, statistical results revealed 
that TGFβ1 levels in paracancerous liver tissue was positively 
correlated with the tumor size. Higher levels of TGFβ1 in 
paracancerous liver tissue were always associated with bigger 
liver tumors. XPO4 in cancerous liver tissue and TGFβ1 in 
paracancerous liver tissue were positively correlated with 
tumor differentiation. TGFβ1, ANGPTL4 and elF5A2 were 
also positively correlated with the T classification of tumors. 
Additionally, a higher expression of XPO4 in cancerous liver 
tissue suggested that the patient would have a better prognosis 
and survival rate. However, higher XPO4 levels in paracan-
cerous liver tissue suggested a worse prognosis. These results 
suggest that XPO4 may be a potential biomarker to assess 
HCC prognosis and differentiation. 
In the present study, we performed experimental and 
statistical work in cancerous and paracancerous materials 
from 280 patients suffering from liver cancer. All patient 
materials were collected and preserved according to standard 
protocols (see Patients and methods). In order to reduce the 
experimental error/variance obtained by processing different 
tissue samples using immunostaining, we selected the method 
of TMAs to equalize the experimental condition among 
different samples. TMA is an innovative type of specimen 
slide with multiple samples on a single slide, which was first 
described in 1986 (17,18). In our study, each slide integrated 
200 tissue specimens on a single slide as 500 dots, which 
represented multiple tissues, pathological types, patients and 
stages, as well as control samples, aiding in the creation of a 
low margin for error. This method allows for high throughput 
of data of multiple patient cases and control samples simul-
taneously. Thus reagent concentrations were identical for 
each case, as were incubation times, temperatures and wash 
conditions. This greatly improves the accuracy of the results, 
leading to more confident conclusions (19). Each experiment 
was also repeated in three slides of TMAs. Data averages were 
used for analysis. 
We have been aware of the result complicity from different 
patients and made numerous attempts to summarize our 
Table V. Association of XPO4, TGFβ1, ANGPTL4 and elF5A2 expression with differentiation.
Indicator Tissue type High differentiation Low differentiation P-value
XPO4 Carcinoma tissue 0.793±0.195 0.850±0.150 0.035
 Adjacent tissue 0.849±0.115 0.881±0.106 0.054
TGFβ1 Carcinoma tissue 0.312±0.290 0.303±0.269 0.867
 Adjacent tissue 0.540±0.285 0.658±0.245 0.003
ANGPTL4 Carcinoma tissue 0.751±0.213 0.737±0.211 0.643
 Adjacent tissue 0.833±0.148 0.842±0.121 0.689
elF5A2 Carcinoma tissue 0.775±0.170 0.800±0.106 0.253
 Adjacent tissue 0.816±0.152 0.845±0.082 0.080
Correlation regression analysis indicated that expression of TGFβ1 in adjacent tissue and XPO4 in carcinoma tissue were significantly correlated 
with differentiation. XPO4 of carcinoma tissue, CC=0.143, P=0.035; TGFβ1 of adjacent tissue, CC=0.195, P=0.004. CC, correlation coefficient.
Table IV. Correlation between XPO4, TGFβ1, ANGPTL4 and elF5A2 expression and vascular invasion in carcinoma tissue and 
adjacent tissue.
Indicator Tissue type Vascular invasion (yes) Vascular invasion (no) P-value
XPO4 Carcinoma tissue 0.689±0.317 0.803±0.185 0.313
 Adjacent tissue 0.806±0.174 0.855±0.111 0.417
TGFβ1 Carcinoma tissue 0.259±0.300 0.257±0.281 0.984
 Adjacent tissue 0.539±0.227 0.502±0.311 0.724
ANGPTL4 Carcinoma tissue 0.780±0.132 0.723±0.247 0.465
 Adjacent tissue 0.889±0.042 0.816±0.172 0.210
elF5A2 Carcinoma tissue 0.760±0.145 0.769±0.174 0.861
 Adjacent tissue 0.867±0.070 0.812±0.143 0.258
The statistical results revealed that all indicators in cancerous and paracancerous liver tissue had no significant correlation with blood vessel 
invasion.
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Figure 3. Kaplan-Meier analysis of TGFβ1 in adjacent tissue correlated with patient survival. Expression of TGFβ1 in carcinoma tissue (A) was not correlated 
with overexpression and underexpression (P=0.954). The results indicated that expression of TGFβ1 in adjacent tissue (B) was not correlated with overexpres-
sion and underexpression (P=0.884).
  A   B
Figure 2. Kaplan-Meier analysis of XPO4 correlated with patient survival function. (A) Kaplan-Meier analysis indicated that expression of XPO4 in carcinoma 
tissue did not correlate with overexpression or underexpression (P=0.202), and that survival rates of XPO4-overexpressing patients were higher than those of 
patients with XPO4 underexpression. (B) Kaplan-Meier analysis indicated that expression of XPO4 in adjacent tissue did not correlate with overexpression or 
underexpression (P=0.139), and that survival rates of XPO4-overexpressing patients were lower than those of patients with XPO4 underexpression. 
  A   B
  A   B
  C   D
Figure 1. Immunostaining images for TGFβ1, XPO4, ANGPTL4 and elF5A2 in carcinoma and paracarcinoma tissues. c indicates the carcinoma tissue and p 
indicates the paracarcinoma tissue. 
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results in a realistic way. It is conventional to take the middle 
point as a standard to perform analysis in survival function. 
However, there is no meaning because the positive probability 
of indicators displays skew distribution. The 25th percentile 
was therefore eventually taken for correlation analysis in our 
study. The suggestion given by this analysis is rational and it is 
close to clinic observation by current knowledge. 
TGFβ is a multipotent polypeptide which regulates cell 
proliferation, differentiation and apoptosis and deters tumor 
growth (20). Within the tumor micro-environment, TGFβ is 
produced by liver cancer cells. It is located within the cyto-
plasm, as shown in our results and consistently in a number of 
previous studies (3,5). However, as a natural response to the 
hypoxic and inflammatory conditions that occur during tumor 
progression, high production levels of TGFβ1 in our study 
were unexpectedly found in paracancerous, but not cancerous, 
liver tissue. Moreover, TGFβ1 in cancerous or paracancerous 
liver tissue had no connection with either tumor vessel inva-
sion or lymph metastasis. These results were inconsistent with 
previous results which demonstrated that the overexpression 
of TGFβ1 is associated with a high incidence of distant metas-
tasis and that TGFβ1 promotes vascular invasion by activating 
β1 integrin (10,21). Additionally, patients positive for TGFβ1 
in the cancerous tissue were suggested to have a better prog-
nosis, as is consistent with a previous report (6). This result 
may partly support the current concept for a dual role of the 
TGFβ signaling pathway in hepatocellular cancer suppression 
and progression of differentiation (3,6,22,23).
TGFβ receptors phosphorylate Smad3 and induce its 
nuclear import, then regulate gene transcription. Smad3 
returns to the cytoplasm to propagate further cycles of signal 
transduction. In HCCs, Smad3 and its phosphorylation rela-
tives have been suggested to be the predictors of prognosis in 
patients with liver cancer and also serve as the biomarkers to 
identify patients with a high risk of recurrence (5). Smad3 is 
exported via XPO4. XPO4 is therefore in control of Smad3 
signaling as well as protein synthesis (7,8). Consistent with a 
previous study (9), our results also demonstrated that XPO4 
was present in cancerous and paracancerous liver tissues, 
with a higher density of XPO4 in paracancerous tissue. Our 
results found that TGFβ1, but not XPO4 (9), in paracancerous 
tissue was significantly positively correlated with tumor size 
and histopathological classification. Moreover, our results 
also suggested that high XPO4 in cancerous tissue resulted 
in a good prognosis. This is consistent with a previous study 
which indicated that downregulation of XPO4 resulted in a 
poor prognosis (9). Our results in an adequate sample size 
emphasized again that XPO4 may be involved in the progres-
sion of human HCC and may serve as a potential biomarker to 
evaluate the condition. A further validation study is suggested 
on a bigger sample size. Additionally, assessment of tumor 
behavior in HCC cell lines with or without rescuing XPO4 
may confirm the therapeutic role of XPO4 in HCC.
elF5A2 is amplified in human tumors, is required for prolif-
eration of XPO4‑deficient tumor cells and promotes HCC in 
mice (7). Our results provided evidence of correlation among 
these four indicators in HCC. Production of elF5A2 in paracan-
cerous tissue is significantly positively associated with cancer 
histopathological classification. Previous studies have also 
revealed that the induction of angiopoietin-like 4 (ANGPTL4) 
by TGFβ, via the Smad signaling pathway, is critical for the 
trans-endothelial passage of tumor cells resulting in tumor 
metastasis (14). Further studies have revealed that ANGPTL4 
regulates endothelial cell junction organization (24) and peri-
cyte coverage (11), resulting in disruption in endothelial cell-cell 
junctions (25). We therefore carried out the rational measure-
ment of ANGPTL4 in the cancerous and paracancerous liver 
tissues in a variety of patients. Our results showed that there 
was no significant correlation between ANGPTL4 and vessel 
or lymphatic invasion. It is inconsistent with previous reports 
that expression of ANGPTL4 was statistically correlated with 
the degree of differentiation, lymphatic invasion and venous 
invasion (12,26). Our results provided evidence that ANGPTL4 
is not a metastasis-inducing factor in HCC. 
In summary, the results of the present study revealed that 
XPO4, TGFβ1, ANGPTL4 and elF5A2 were present in both 
cancerous and paracancerous liver tissues, and that they were 
closely correlated with each other. TGFβ1 in paracancerous 
liver tissue was positively correlated with the tumor size. XPO4 
in cancerous liver tissue and TGFβ1 in paracancerous liver 
tissue were positively associated with tumor differentiation. 
Meanwhile, TGFβ1, ANGPTL4 and elF5A2 were significantly 
correlated with the T classification of tumors. Of these four 
indicators, XPO4 appears to be a potential biomarker to 
evaluate HCC. 
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